Sirolimus CAS No: 53123-88-9 First discovered in 1972 and approved by the FDA in 1999, sirolimus can be used for a variety of disorders and medical events, including organ transplant procedures, lung disease, and heart protection. By suppressing the immune system, patients who have recently received a new organ have a better chance of their body accepting[…]
Sirolimus Provides Protection for the Heart, Kidneys, and Lungs
Immunosuppressant Tags: Sirolimus Dec 05, 2018
How Fingolimod Hydrochloride Limits MS Relapses in Children and Adults
Drug Research & Development API, Immunosuppressant Jul 31, 2018
Fingolimod Hydrochloride CAS: 162359-56-0 Fingolimod Hydrochloride is typically given to those who suffer from multiple sclerosis (MS) relapses. It doesn’t eliminate episodes in the body entirely, but it can reduce them by 50% or more over the course of several years. When the body is having an autoimmune reaction, the lymphocytes play a big role[…]
Tacrolimus – an Effective Immunosuppressant API for a Number of Inflammatory Disorders
Immunosuppressant, OTC and Compounding Product Tags: eczemaTacrolimus Mar 30, 2018
Tacrolimus CAS No: 104987-11-3 Tacrolimus is an immunosuppressant that has been primarily used to help transplant patients accept their new organs. However, there’s more to this macrolide API than meets the eye. By inhibiting the production of T cells within the body, tacrolimus can be used to help a variety of inflammatory diseases, most notably[…]
No Increased Risk of AML in Lenalidomide Drug Recipients
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Immunological Agent, Immunosuppressant Tags: Lenalidomide Dec 23, 2014
Reassuring findings were presented at the American Society of Hematology Annual Meeting at the beginning of December 2014 regarding the use of the immunomodulatory drug Lenalidomide. Concerns for patients with myelodysplastic syndrome (MDS) being administered this potent anti-cancer drug were quelled, when a comprehensive study revealed that this lifesaving treatment did not lead to a[…]
Daclizumab Passes Phase III Hurdles
Immunosuppressant, Monoclonal Antibodies / mAb Tags: MSmultiple sclerosis Jul 03, 2014
Exciting news has been shared by Abbvie and Biogen regarding Daclizumab and it’s now brighter future. The once a month treatment for MS has now cleared all major Phase III hurdles, making a marketing pitch to FDA regulators foreseeable in the near future. As an injectable medication designed to combat the debilitating symptoms of Multiple[…]
FDA Accepts of NDA for Autopen Containing Methotrexate
Anti-Psoriatic, Drug Research & Development API, Immunosuppressant, NDA Tags: MethotrexateNDANew Drug Application Feb 20, 2014
The culmination of the month of January 2014 brought good news for Medac Pharma regarding their innovative Methotrexate autopen. This easy to use, novel, self-injectable device was accepted as a New Drug Application (NDA) by the FDA. As a subcutaneous injectable form of Methotrexate, the autopen is a ready to use device geared for patients[…]
EU Approves Dimethyl Fumarate for First Line MS Treatment
Drug Research & Development API, EU Approved 2014, Immunosuppressant Tags: EURRMS Feb 17, 2014
Dimethyl Fumarate was approved by the EU at the beginning of February 2014 as a first line treatment for multiple sclerosis. Known as the brand name TECFIDERA, which is marketed by Biogen Inc., this efficacious and novel treatment is specified for patients with the most common form of multiple sclerosis, relapsing-remitting multiple sclerosis, or RRMS.[…]
Eculizumab Receives Orphan Drug Status
Drug Research & Development API, FDA Orphan Drug Status, Immunosuppressant, Monoclonal Antibodies / mAb Tags: anemia Feb 13, 2014
At the end of January 2014 the powerful drug Eculizumab received orphan drug status from the FDA as a preventative treatment of delayed graft function (DGF) for renal transplant patients. Eculizumab is already approved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Paroxysmal nocturnal hemoglobinuria or PNH is a rare form of anemia[…]
Thalidomide Offers Effectual Treatment for a Variety of Conditions
Drug Research & Development API, Immunosuppressant Tags: dexamethasonemultiple myeloma Dec 16, 2013
Thalidomide, known as the brand name Thalomid, is a known therapy for patients who are newly diagnosed with multiple myeloma. Patients who have been recently diagnosed with multiple myeloma are often given a combination treatment of Thalidomide and dexamethasone. Recently, research has shown that there are new possible uses for Thalidomide to treat a variety of[…]
FDA Approves Self-Administrating Injectable Methotrexate
Anti-Psoriatic, Immunosuppressant Tags: MethotrexatePsoriasisRheumatoid Arthritis Oct 29, 2013
The recent approval by the FDA for the Methotrexate injection was encouraging news for patients with rheumatoid arthritis. The FDA gave a nod to approve Methotrexate as the brand name OTREXUP, which is marketed by Antares Pharma on October 16, 2013. This subcutaneous injectable treatment is quite novel, as it is the very first and[…]